Thackray Helen M.

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$175,800.00
Insider Sells Quantity
12
Insider Sells Sum
$833,970.93

Insider Activity of Thackray Helen M.

According to the SEC Form 4 filings, Thackray Helen M., being in a position of

  1. Chief R&D Officer at BioCryst Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 30000 shares for $175,800, and sold 0 shares,
    over all time since 2022-04-01, has bought 30000 shares for $175,800, and sold 17725 shares for $215,181.

The largest purchase of all time was on 2024-05-14 and amounted to 30000 shares of BioCryst Pharmaceuticals, Inc. for $175,800.

The largest sale of all time was on 2016-07-05 and amounted to 20272 shares of GlycoMimetics, Inc. for $142,107.

Biography of Thackray Helen M.

No biography is available at this moment.

2024-05-14PurchaseBioCryst Pharmaceuticals, Inc.
BCRX
Chief R&D Officer
30,000
0.0159%
$5.86$175,800+39.44%
2023-04-03SaleBioCryst Pharmaceuticals, Inc.
BCRX
Chief R&D Officer
7,000
0.0037%
$8.29$58,030-19.09%
2022-12-15SaleBioCryst Pharmaceuticals, Inc.
BCRX
Chief R&D Officer
3,125
0.0018%
$10.89$34,031-30.48%
2022-04-01SaleBioCryst Pharmaceuticals, Inc.
BCRX
Chief R&D Officer
7,600
0.004%
$16.20$123,120-34.09%
2017-12-08SaleGlycoMimetics, Inc.
GLYC
SVP Clinical Development, CMO
4,000
0.0114%
$15.01$60,040+8.82%
2017-09-18SaleGlycoMimetics, Inc.
GLYC
SVP Clinical Development, CMO
4,000
0.0114%
$13.00$52,000+16.14%
2017-05-25SaleGlycoMimetics, Inc.
GLYC
SVP Clinical Development, CMO
4,000
0.0165%
$15.57$62,280+1.58%
2017-05-19SaleGlycoMimetics, Inc.
GLYC
SVP Clinical Development, CMO
4,000
0.014%
$12.14$48,560+9.64%
2016-10-03SaleGlycoMimetics, Inc.
GLYC
VP Clinical Development, CMO
8,000
0.0357%
$7.00$56,002-5.15%
2016-07-20SaleGlycoMimetics, Inc.
GLYC
VP Clinical Development, CMO
4,000
0.0171%
$8.00$32,000-20.49%
2016-07-06SaleGlycoMimetics, Inc.
GLYC
VP Clinical Development, CMO
13,592
0.0589%
$6.68$90,795-3.74%
2016-07-05SaleGlycoMimetics, Inc.
GLYC
VP Clinical Development, CMO
20,272
0.0901%
$7.01$142,107-5.85%
2016-07-01SaleGlycoMimetics, Inc.
GLYC
VP Clinical Development, CMO
10,136
0.0433%
$7.40$75,006-14.38%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.